News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Egetis Therapeutics’ Annual Report 2024 published

April 11, 2025

Stockholm, Sweden, April 11, 2025 – Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (Nasdaq Stockholm: EGTX) Annual Report for 2024 is available (in Swedish) attached to this press release and at the Company’s website, www.egetis.com. An English translation of the Annual Report will be published shortly.

Share

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]